Infection,
Congress,
Recombinant antibodies,
SARS-CoV-2,
Long,
Viral,
ELISA,
ESCMID,
Cytokine,
Epitope,
Lyme disease,
Research,
ELISpot,
Immunology,
Diagnosis,
Long COVID,
Biomarker,
Immunity,
Flow cytometry,
CD8,
Vaccine The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
Key Points:
- The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
- "We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune™ T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.
- "The launch marks a significant milestone for Virax as it brings us a step closer to commercializing ViraxImmune™ as a full In-Vitro-Diagnostic product."
- ImmuneSelect is the Company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.
Knowledge,
Heart,
Dubai Design District,
Senior,
D3,
Viral,
Research,
Science,
Dubai Science Park,
TECOM Group,
Patient,
Diagnosis,
Growth,
Ecosystem,
PJSC,
Health,
Director of National Parks,
SME,
Dubai International Academic City,
Vaccine,
Drug LONDON and DUBAI, UAE, May 4, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it established a regional headquarters at Dubai Science Park, a member of TECOM Group PJSC.
Key Points:
- LONDON and DUBAI, UAE, May 4, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it established a regional headquarters at Dubai Science Park, a member of TECOM Group PJSC.
- "The new headquarters will strengthen the distribution network we have developed for ViraxClear and enable further development of our innovative technology behind Virax Immune, while tapping into an esteemed science and business community established at Dubai Science Park."
- Dubai Science Park is a global ecosystem that serves the entire value chain of the science, health and pharma sectors.
- Dubai Science Park is part of TECOM Group's portfolio of 10 districts that includes Dubai Internet City, Dubai Media City, Dubai Studio City, Dubai Production City, Dubai Knowledge Park, Dubai International Academic City, Dubai Design District (d3), Dubai Industrial City and Dubai Outsource City.
Retrieved on:
Wednesday, April 19, 2023
Public,
Viral,
Global health,
Infection,
International Health Regulations,
RNA,
Viral hemorrhagic fever,
Marburg virus disease,
Diagnosis,
PCR,
Disease,
World Health Organization,
Vaccine LONDON, April 19, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.
Key Points:
- LONDON, April 19, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.
- The Marburg Virus Real Time PCR Kit is an in-vitro diagnostic test, based on real-time PCR technology, for the detection of ribonucleic acid (better known as RNA) from the Marburg Virus.
- Our Marburg Virus PCR testing kit is a significant step forward in our mission to improve global health."
- The Marburg Virus Disease is a highly virulent disease which causes hemorrhagic fever and requires assessment under the International Health Regulations by the World Health Organization.
H3,
Poultry,
Infection,
H10,
PCR,
Diagnosis,
Influenza A virus,
H7N9,
AIV,
European,
H5N1,
Human,
Livestock,
Virus,
Viral,
CE,
Vaccine,
H5,
H7 LONDON, March 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of an Avian Influenza A Virus ("AIV") real-time PCR test kit to markets accepting the CE mark, namely the European Union.
Key Points:
- LONDON, March 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of an Avian Influenza A Virus ("AIV") real-time PCR test kit to markets accepting the CE mark, namely the European Union.
- The test kit is for the detection and differentiation of ribonucleic acid from AIV and the H5, H7 and H9 subtypes, including the H5N1 strain currently spreading in Europe.
- The test kit is for use in laboratory settings and can help healthcare professionals accurately identify an AIV infection.
- With a real-time PCR test kit poised to accurately and reliably detect AIV, including the deadly H5N1 strain, we expect to facilitate rapid and potentially life-saving interventions especially in vulnerable jurisdictions."
Retrieved on:
Tuesday, February 7, 2023
LONDON, Feb. 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced that it has signed a Purchase Order with Cosmos Health (Nasdaq: COSM) ("Cosmos") to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits.
Key Points:
- LONDON, Feb. 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced that it has signed a Purchase Order with Cosmos Health (Nasdaq: COSM) ("Cosmos") to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits.
- Virax's Chairman of the Board of Directors and Chief Executive Officer, Mr. James Foster, commented, "COVID-19, Influenza A and Influenza B are major sources of illness and mortality in humans across the globe.
- "While the threat of Influenza has been overshadowed by COVID-19, the healthcare burden of Influenza should not be overlooked.
- The COVID-19 & Influenza A+B antigen combo rapid test is a single-use test kit intended for qualitative detection of nucleocapsid protein antigen of Influenza A and B viral antigens and COVID-19 antigen from nasal swab specimens.
LONDON, Feb. 6, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Dr. Tomasz George, Chief Scientific Officer of Virax, and Cameron Shaw, Chief Operations Officer at Virax, will be presenting at the BIO CEO & Investor Conference on Tuesday, February 7, 2023.
Key Points:
- LONDON, Feb. 6, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Dr. Tomasz George, Chief Scientific Officer of Virax, and Cameron Shaw, Chief Operations Officer at Virax, will be presenting at the BIO CEO & Investor Conference on Tuesday, February 7, 2023.
- The presentation will highlight the recent Company developments, anticipated milestones and ongoing clinical and business developments.
- Details about the presentation are as follows:
Presenters: Dr. Tomasz George, Chief Scientific Officer of Virax, and Cameron Shaw, Chief Operations Officer at Virax
In its 25th year, BIO CEO is one of the largest investor conferences in the life science industry.
- Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering .
Retrieved on:
Thursday, February 2, 2023
Bank statement,
D&O,
Hand,
CE,
Physician,
United Kingdom,
Virus,
PCR,
RSV,
Patient,
Mpox,
Artificial intelligence,
Clinical trial,
Measles,
Letter,
Risk,
Hepatitis B,
Immune system,
Form 6-K,
Antibody,
Growth,
Infection,
Machine learning,
Prevalence,
COVID-19,
European,
PIPE,
Vaccine,
Cytomegalovirus,
Malaria LONDON, Feb. 2, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a letter to shareholders.
Key Points:
- LONDON, Feb. 2, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a letter to shareholders.
- The Virax Immune platform is expected to provide a unique and actionable assessment of an individual's immunity that is both accurate and affordable.
- In October 2022, we announced the initiation of an analytical performance study to optimize the Virax Immune T-Cell kit.
- As you can see, expectations are high for Virax Biolabs, and we are committed to exceeding those expectations over the next year.
Retrieved on:
Wednesday, January 4, 2023
Death,
World Health Organization,
CE,
European Centre for Disease Prevention and Control,
Environment,
HPV,
Growth,
COVID-19,
Diagnosis,
Control,
Risk,
Nature,
Cervical cancer,
Union,
Hepatitis B,
Multimedia,
Monkeypox,
Therapy,
Herpes simplex,
Infection,
Degenerative disease,
Woman,
Vaccine,
Malaria,
EU LONDON, Jan. 4, 2023 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent. The specialized diagnostic kits can be found by contacting the Company's sales representatives.
Key Points:
- The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent.
- These tests will cover more genotypes, have shorter processing times and lower costs than the currently available HPV tests in Europe.
- Founded in 2013, Virax Biolabs is an Innovative Biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases.
- T-Cell testing can be particularly effective in the management and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Retrieved on:
Tuesday, November 15, 2022
New England Biolabs,
Growth,
Technology,
Board,
Hepatitis B,
Intention,
Environment,
Therapy,
Forward-looking statement,
Degenerative disease,
View,
Company,
NGS,
Herpes simplex,
Terminology,
Research,
Multimedia,
COVID-19,
Nature,
Roche Diagnostics,
Commercial Operating System (COS),
DNA sequencing,
Diagnosis,
Monkeypox,
Vaccine,
Malaria LONDON, Nov. 15, 2022 /PRNewswire/ --Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales.
Key Points:
- LONDON, Nov. 15, 2022 /PRNewswire/ --Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales.
- "We are thrilled to welcome Richard to our team," said James Foster, Chairman of the Board and Chief Executive Officer of Virax Biolabs.
- As the Vice President of In Vitro Diagnostic Sales, Mr. Pallin will lead Virax's commercial team and lead the execution of the Company's go-to-market strategy.
- Prior to joining Virax, Mr. Pallin was the Vice President of Global Commercial Operations of Omixon, Inc., a global transplantation diagnostic company dedicated to transitioning the human leukocyte antigen community to Next Generation Sequencing (NGS) technologies.
Retrieved on:
Wednesday, October 26, 2022
Disease,
Therapy,
Pandemic,
Growth,
Virus,
Diagnosis,
Director,
Immunity,
Antibody,
Patient,
Monkeypox,
Research,
COVID-19,
Technology,
Immune system,
Company,
IVD,
Degenerative disease,
Board,
Intention,
Nature,
Hepatitis B,
Environment,
Vaccination,
HPV,
Forward-looking statement,
Terminology,
Vaccine,
Herpes simplex,
Malaria LONDON, Oct. 26, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the initiation of its Virax Immune COVID-19 Analytical Performance Study scheduled to take place through Q4 of this year and finishing in Q1 of next year.
Key Points:
- LONDON, Oct. 26, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the initiation of its Virax Immune COVID-19 Analytical Performance Study scheduled to take place through Q4 of this year and finishing in Q1 of next year.
- The Analytical Performance Study will evaluate the technical performance of the Virax Immune COVID-19 Flow Cytometry Kit and will include specimens from 96 healthy volunteers1.
- The first test being developed using the Virax Immune platform is for immunity related to COVID-19.
- Founded in 2013, Virax Biolabs is an Innovative Biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases.
